caa a22 4500 469121386 CHVBK 20180323133140.0 cr unu---uuuuu 170328e19920301xx s 000 0 eng 10.1007/BF02245409 doi (NATIONALLICENCE)springer-10.1007/BF02245409 Urinary metabolites of amitriptylinoxide and amitriptyline in single-dose experiments and during continuous therapy [Elektronische Daten] [B. Becher, W. Fischer, Z. Taneri, E. Scholz, W. Müller, U. Breyer-Pfaff] In a cross-over design, six healthy volunteers received 50 mg amitriptylinoxide (AT-NO) IV and orally and 50 mg amitriptyline (AT) IV. Urine was collected completely for 8 h and occasionally up to 48 h. In addition, five patients each under treatment with AT-NO or AT for tension headache collected 24-h urine samples. The following compounds were analysed by HPLC: AT-NO, E- and Z-10-hydroxy-AT-NO (E- and Z-10-OH-AT-NO), free and conjugated AT, E- and Z-10-OH-AT and their mono- and didemethylated analogues, and 2-OH-nortriptyline (2-OH-NT). Unchanged AT-NO in urine accounted for an average of 34% and 22% of the single IV and oral doses, respectively, and for 28% in continuous therapy, with a further 8-9% being excreted as E- and Z-10-OH-AT-NO. The remaining part was converted to the same metabolites as was AT. In the steady state the measured compounds accounted for 74% and 77% of the daily AT-NO and AT doses, respectively. The renal plasma clearance of AT-NO varied between 75 and 265 ml/min in the six volunteers. Tubular secretion must play an important part in the renal excretion of AT-NO. Springer-Verlag, 1992 Amitriptyline nationallicence Amitriptylinoxide nationallicence Metabolites nationallicence Renal clearance nationallicence Becher B. Institut für Toxikologie, Universität Tübingen, Wilhelmstrasse 56, W-7400, Tübingen, Federal Republic of Germany aut Fischer W. Rhône-Poulenc/Nattermann, Nattermannallee 1, W-5000, Köln 30, Federal Republic of Germany aut Taneri Z. Hans-Böckler-Strasse 20, W-4100, Duisburg, Federal Republic of Germany aut Scholz E. Neurologische Klinik, Universität Tübingen, W-7400, Tübingen, Federal Republic of Germany aut Müller W. Psychopharmakologisches Labor, Zentralinstitut für Seelische Gesundheit, J 5, W-6800, Mannheim 1, Federal Republic of Germany aut Breyer-Pfaff U. Institut für Toxikologie, Universität Tübingen, Wilhelmstrasse 56, W-7400, Tübingen, Federal Republic of Germany aut Psychopharmacology Springer-Verlag 106/3(1992-03-01), 303-310 0033-3158 106:3<303 1992 106 213 https://doi.org/10.1007/BF02245409 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245409 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Becher B. Institut für Toxikologie, Universität Tübingen, Wilhelmstrasse 56, W-7400, Tübingen, Federal Republic of Germany aut NATIONALLICENCE 700 1- Fischer W. Rhône-Poulenc/Nattermann, Nattermannallee 1, W-5000, Köln 30, Federal Republic of Germany aut NATIONALLICENCE 700 1- Taneri Z. Hans-Böckler-Strasse 20, W-4100, Duisburg, Federal Republic of Germany aut NATIONALLICENCE 700 1- Scholz E. Neurologische Klinik, Universität Tübingen, W-7400, Tübingen, Federal Republic of Germany aut NATIONALLICENCE 700 1- Müller W. Psychopharmakologisches Labor, Zentralinstitut für Seelische Gesundheit, J 5, W-6800, Mannheim 1, Federal Republic of Germany aut NATIONALLICENCE 700 1- Breyer-Pfaff U. Institut für Toxikologie, Universität Tübingen, Wilhelmstrasse 56, W-7400, Tübingen, Federal Republic of Germany aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106/3(1992-03-01), 303-310 0033-3158 106:3<303 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer